Prelude Therapeutics Inc(PRLD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,765 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in PRLD
Events flagged as statistical outliers against PRLD's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-16
PRLD quality score dropped 10 points (27→17) on a new filing
View source filing →
PRLD Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Prelude Therapeutics Inc (PRLD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PRLD at 21.5/100 on a 32-signal composite quality model, placing it at rank #2,765 of 2,962 stocks — the bottom half of the AI-ranked universe. PRLD scores in the top quartile across institutional flow (94.0). Areas of concern include revenue scale (3.7) and profitability (4.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Prelude Therapeutics Inc reports quarterly revenue of $5.7M, net income of $-13.9M, free cash flow of $-15.6M. Top institutional holders of PRLD by reported 13-F value include ORBIMED ADVISORS, BAKER BROS. ADVISORS, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. PRLD trades on the Nasdaq exchange and files with the SEC under CIK 1678660. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PRLD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Prelude Therapeutics Inc directly from SEC EDGAR. Prelude Therapeutics Inc's 13F Pro composite quality score has ranged between 17 and 37 since 2025, currently 21.5 — a stable long-term trajectory across 52 quarterly and live scoring snapshots.
Revenue
Q2 2026
$5.7M
Net Income
Q2 2026
$-13.9M
Free Cash Flow
Q2 2026
$-15.6M
ROIC
Q2 2026
-46.2%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+73.4% YoYNet Income
+21.8% YoYOperating Income
+25.2% YoYEPS (Diluted)
+23.2% YoYTotal Assets
-19.5% YoYOp. Cash Flow
+45.3% YoYFree Cash Flow
+45.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $12.1M +73.4% | $7.0M | — | — | — | — |
| Net Income | $-99.5M +21.8% | $-127.2M -4.4% | $-121.8M -5.5% | $-115.4M -3.4% | $-111.7M -96.2% | $-56.9M |
| Operating Income | $-104.6M +25.2% | $-139.7M -5.6% | $-132.3M -7.1% | $-123.5M -8.6% | $-113.7M -93.5% | $-58.8M |
| EPS (Diluted) | $-1.29 +23.2% | $-1.68 +16.8% | $-2.02 +17.2% | $-2.44 -0.4% | $-2.43 | — |
| Total Assets | $141.3M -19.5% | $175.5M -36.8% | $277.7M +25.9% | $220.5M -27.7% | $305.1M +36.5% | $223.6M |
| Operating Cash Flow | $-56.3M +45.3% | $-102.9M +3.9% | $-107.1M -27.9% | $-83.7M -0.2% | $-83.5M -80.9% | $-46.2M |
| Free Cash Flow | $-56.4M +45.6% | $-103.7M +6.3% | $-110.6M -27.5% | $-86.7M -1.0% | $-85.9M -83.5% | $-46.8M |
Get alerted when PRLD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Prelude Therapeutics Inc including:
Top Institutional Holders of PRLD
ORBIMED ADVISORS LLC
$73.2M13,724,571 shBAKER BROS. ADVISORS LP
$54.0M10,123,824 shRA CAPITAL MANAGEMENT, L.P.
$34.5M6,475,882 shSoleus Capital Management, L.P.
$18.0M3,378,378 shKynam Capital Management, LP
$12.9M2,415,087 shVANGUARD CAPITAL MANAGEMENT LLC
$10.7M2,009,445 shBlackRock, Inc.
$9.6M1,797,501 shSPHERA FUNDS MANAGEMENT LTD.
$5.4M1,019,832 shTWO SIGMA INVESTMENTS, LP
$5.3M993,369 shADAR1 Capital Management, LLC
$4.8M900,900 sh
| Fund | Value | Shares |
|---|---|---|
| ORBIMED ADVISORS LLC | $73.2M | 13,724,571 |
| BAKER BROS. ADVISORS LP | $54.0M | 10,123,824 |
| RA CAPITAL MANAGEMENT, L.P. | $34.5M | 6,475,882 |
| Soleus Capital Management, L.P. | $18.0M | 3,378,378 |
| Kynam Capital Management, LP | $12.9M | 2,415,087 |
| VANGUARD CAPITAL MANAGEMENT LLC | $10.7M | 2,009,445 |
| BlackRock, Inc. | $9.6M | 1,797,501 |
| SPHERA FUNDS MANAGEMENT LTD. | $5.4M | 1,019,832 |
| TWO SIGMA INVESTMENTS, LP | $5.3M | 993,369 |
| ADAR1 Capital Management, LLC | $4.8M | 900,900 |
Companies Similar to PRLD
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Relay Therapeutics, Inc.
Caribou Biosciences, Inc.
SUTRO BIOPHARMA, INC.
C4 Therapeutics, Inc.
Evommune, Inc.
CytomX Therapeutics, Inc.
BioAge Labs, Inc.
MACROGENICS INC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put PRLD on your watchlist
Track score changes the day Prelude Therapeutics Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PRLD a good stock to buy?
13F Pro's AI-powered analysis of Prelude Therapeutics Inc (PRLD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PRLD are available on the PRLD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PRLD is classified as a small company.
Which hedge funds own PRLD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PRLD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Prelude Therapeutics Inc's investment landscape.